Innate Pharma SA Class A IPHYF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.25
- Day Range
- $1.65–1.65
- 52-Week Range
- $1.37–2.25
- Bid/Ask
- $1.58 / $2.94
- Shares Outstanding
- 93.90M
- Market Cap
- $154.82M
- Volume/Avg
- 6,750 / 4,550
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 47.02
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 163
- Website
- https://www.innate-pharma.com
Valuation
|
Metric
|
IPHYF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 47.02 |
Price/Cash Flow | — |
Price/Earnings
IPHYF
Financial Strength
|
Metric
|
IPHYF
|
|---|---|
Quick Ratio | 1.14 |
Current Ratio | 1.27 |
Interest Coverage | −113.76 |
Quick Ratio
IPHYF
Profitability
|
Metric
|
IPHYF
|
|---|---|
Return on Assets (Normalized) | −51.64% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −192.58% |
Return on Assets
IPHYF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?Np<>z | LOCK|wnyk# | $134B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|w%%wjHk | LOCK|$Y@<& | $83B | |||
| argenx SE ADR
ARGX
| LOCK|$k%nj@p | LOCK|$pv | $63B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|skK?^$nd | LOCK|bX&x | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|k!$$v$# | LOCK|vR | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|csTVK! | LOCK|^DT$ | $31B | |||
| Moderna Inc
MRNA
| LOCK|##qTzSb | LOCK|&S | $25B | |||
| Incyte Corp
INCY
| LOCK|LRN%^# | LOCK|yJ$ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|?Rfr^k! | LOCK|k> | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!?f>RL | LOCK|k^R | $16B |
United States